TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Opioids Prescribed at Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-operative nausea and vomiting scores
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Home Hospice Patients Prescribed Antipsychotic Medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Home Hospice Patients Prescribed Non-Opioid Analgesic Medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Irrational preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fracture union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Return to normal function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of ATC prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hemorrhage prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pneumonia prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Success of RF Ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Long-Term Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AAD-Free Long-Term Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hemodynamic response to cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective response to cocaine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean high sensitivity C-reactive protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean CEC surface expression of vascular cell adhesion molecule-1 (VCAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean larger artery elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pharmacokinetic data of lenograstim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects following hygienic drinking water handling practices
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of Contraversive Pushing at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Lateropulsion at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Balance at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful decrease in psychosocial symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma elimination half life (t½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) Score for Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eustachian Tube Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in modified AIMS total score from baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The incidence rate of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to onset of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Syphilis, Gonorrhea and Chlamydia
Endpoint domain: Adverse events/effects
Primary endpoint: mean time before the onset of first clinical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in media/lumen ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum % relaxation response to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Tumor Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Retained
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acceptability of the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: recovery from surgery (wound healing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite of First of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Clinical test indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Length of blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FEV1 AUC(0-12h) Change From Baseline to Post Dose Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in eGFR after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidences of grade 3-4 acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-Emergent AEs (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients who completely don the leg compression devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of Panobinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Number Of Participants With Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number Of Participants With Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number Of Participants With AEs Leading To Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number Of Participants With Clinically Significant Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants with ACR20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yield of Recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Brain blood flow speed changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of matched blood glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in International Index Erectile Function (IIEF) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: composite outcome of incident stroke, myocardial infarction, and all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Skin pigmentation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in BREAST-Q score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in health-related quality of life measured by EORTC QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in health-related quality of life measured by EORTC QLQ-BR23
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to Relapse (Resumption of Drinking)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: use of analgesia during hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Indices of Respiration-induced Anatomic Structure Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Structure Volume Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structure Shape Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required for management of post-operative complications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of lymphedema of the lower extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Antibody Titers >= 10 (1/Dil)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Solicited Inj. Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Objective coercive measures
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients fulfilling conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Oral Soft Tissue Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent productivity loss due to presenteeism (6M)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percent productivity loss due to presenteeism (12M)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percent productivity loss due to absenteeism (6M)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percent productivity loss due to absenteeism (12M)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time to Reach Maximum Tolerated Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expressive Language Sample Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication response prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Depression Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in SELENA SLEDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Physician's Global Assessment (PGA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SMA program retention rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of functional treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Change of Hippocampus Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: % Change of Whole Brain Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rate of canine retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with first-attempt success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaccine related reactions
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of grade III-IV acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Beck Depression Inventory-Second Edition (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of H. pylori eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C0 (ng/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated AUC 0-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tacrolimus Powder Dissolution Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial innervation pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean interpeak latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean visual neural myelination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Scored Less Than 30 on the 0-100 Visual Analog Scale (VAS) for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Pain Rating on the 0-100 VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MATRICS Consensus Cognitive Battery total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percent total weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intracranial Progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Liver mitochondrial gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Daily Copper Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of Inflammatory Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: % of patients with Mchugh grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Interoperative Hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in ctDNA level of mutant BRAF≥80%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain associated with insertion of a Mirena®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung and chest wall elastance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical Global Impression Scales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in VAS Stiffness Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VAS Fatigue Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in FACIT-Fatigue Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean Change in Stinging Sensation Immediately After Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Stinging Sensation One Minute After Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive Symptoms change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in liver fat fraction (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional sympatholysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HOOS survey scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of ischemic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of bleeding outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrist extension angle during grasping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of aerobic performance capability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of cardiac syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: symptoms of fast heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VT/VF events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardioversion or defibrillation shocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of FDG-PET/CT Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of Accommodation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial Pressure Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cerebro Spinal Fluid Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with an airway injury
Endpoint domain: Adverse events/effects
Primary endpoint: Change over time of VAS pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: genetic diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to identify children and parents in need for further support/interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: LH Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dietary diversity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptable diet score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Genetic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of Participants With Progression Free Survival at 6 Months (PFS-6)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of SEPT9 gene promoter methylation positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: EMG activity during motor task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need of transfusion post-op
Endpoint domain: Adverse events/effects
Primary endpoint: tumour response and control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IFP as a prognostic factor for pelvic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics parameters of Cetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health related QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quantity of specific lipids in atrial tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of ERBB receptors expressed on atrial endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Discontinued Study Drug Due to an AE
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in ghrelin (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent Change in Hmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Somatosensory Evoked Potential (SSEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma area under the curve (AUC) of BCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax of BCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unsuccessful lumbar puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Risk factors for aortic dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: retrieval rates of the clipped node
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Osimertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal Function by Estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Age at Mortality Event (survival)
Endpoint domain: Mortality/survival
Primary endpoint: Inhibition of sensory experience frequency and intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcutaneous Carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcutaneous Oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Borg dyspnea score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Identification of early stage melanomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Biomarkers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of contamination
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in overall composite metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radicality of Brain Tumor Resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mass Balance Recovery of Total (C-14) BI 1265162-radioactivity in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mass Balance Recovery of Total (C-14) BI 1265162-radioactivity in Faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with One or More Related Adverse Events
Endpoint domain: Adverse events/effects